

Index

Please note: page numbers in **bold** indicate figures or tables.

- acanthocytosis, 11–12
 activated PI3K δ syndrome, 235
 acute leukemia of ambiguous lineage (ALAL), 152–4
 acute lymphoblastic leukemia (ALL), **128**
 acute monocytic leukemia, **166**
 acute myeloid leukemia (AML), 147, **175**
 with germline *CEBPA* mutation, 210
 with myelodysplasia-related changes (AML-MRC), 147
 myeloid sarcoma, 150
 not otherwise specified (NOS), 150, **166**
 clinicopathologic features, 166
 with recurrent genetic abnormalities, 147, **162**
 therapy-related myeloid neoplasms, 148–50
 ADAMTS13 deficiency, 23
 anaplastic large cell lymphoma
 ALK positive, 78
 ALK negative, 78–86
 anemia, 1–2
 sideroblastic, 270, **272**
 aplastic anemia, diagnosing, 46
 arsenic toxicity, in APL patients, **289**
 aspergillosis, 58, **62**
 ataxia telangiectasia (AT), 106, **111**, 241
 autoimmune hemolytic anemia (AIHA), **13**, **16**
 cold agglutinin syndrome, 13
 mixed AIHA, 13
 paroxysmal cold hemoglobinuria, 13
 secondary AIHA, 13
 warm AIHA, 13
 autoimmune lymphoproliferative syndrome (ALPS), 114, **122**, 234–7
 autoimmune myelofibrosis, 275

 babesiosis, 27
 Barth syndrome, 18
 Bernard-Soulier syndrome (BSS), 20
 blastic plasmacytoid dendritic cell neoplasm (BPDCN), 140, **146**
 blood smear evaluation, *see also* peripheral blood smear evaluation, 1
 blood smear preparation, 1
 B-lymphoblastic leukemia/lymphoma (B-ALL/B-LBL), 127–35
 scalp biopsy, **131**
 bone marrow
 aspirate smears, **43**
 cellularity, **48**
 components in pediatric patients, 42, **51**
 erythroid maturation, **46**
 hematogones, 42, 44, **49**
 hematopoietic stem cells, development, **43**
 iron stores, evaluation of, 44
 manifestations of disease in, 270, **287**
 see also bone marrow failure; bone marrow metastases
 marrow cellularity in newborns, 42
 mast cells, **45**
 megakaryocytes, **44**
 monocytes, **45**
 myeloid maturation, **45**
 myeloid–erythroid ratio, 42, **46**
 stromal cells, **47**
 bone marrow failure, 270, **287**
 congenital dyserythropoietic anemia, **271**
 Pearson syndrome, **272**
 sideroblastic anemia, 270, **272**
 therapy-related changes, 272–4
 bone marrow in
 carcinoma, 285
 desmoplastic small round cell tumor, 282
 Ewing sarcoma, 277
 Gaucher disease, **286**
 heavy metal toxicity/deficiency, **289**
 neuroblastoma, 275, **279**
 Niemann-Pick disease, **287**
 retinoblastoma, 282
 rhabdomyosarcoma, 277, **281**
 storage diseases, **286–8**
 Wolman disease/lysosomal acid lipase deficiency, **288**
 bone marrow necrosis, **276**
 Burkitt lymphoma (BL), 65, **103**
 Burkitt-like lymphoma with 11q aberration, 65–7
 carcinoma, 285
 Castleman disease (CD), 31, **32**, 33,
 hyaline vascular variant, **35**
 plasma cell variant, **36**
 cat scratch disease, 52
 Chediak-Higashi syndrome, 17
 childhood myelodysplastic syndrome (MDS), 198, **205**
 refractory cytopenia of childhood, 199–200, **202**, **203**
 secondary MDS, 201
 therapy-related (t-MDS), 201
 chronic eosinophilic leukemia myeloid/lymphoid neoplasms presenting as, **255**
 not otherwise specified (CEL, NOS), 249
 chronic granulomatous disease (CGD), **110**, **118**
 chronic myeloid leukemia (CML), 4, **179–80**
 BCR-ABL1 positive, 176
 chronic myelomonocytic leukemia (CMML), 187, **196**
 chronic neutrophilic leukemia (CNL), 178
 coccidioidomycosis, 59
 cold agglutinin syndrome (CAS), 13
 colony-stimulating factor therapy effect, **273**
 common variable immunodeficiency (CVID), 110, **116**
 congenital dyserythropoietic anemia (CDA), **271**
 morphologic features, 287
 copper deficiency/zinc excess, presentation in bone marrow, **289**
 COVID 19, in newborn smear, 6
 cystinosis, 277
 cytomegaloviral infections (CMV), 26
 cytomegalovirus, 55

 desmoplastic small round cell tumor (DRSCT), 282
 Diamond-Blackfan anemia (DBA), 220
 diffuse large B-cell lymphoma (DLBCL), 67, 72

Index

- DiGeorge syndrome, 22q11.2 deletion syndrome, 107
- Döhle bodies, 17
- Down syndrome (DS)
lymphoid neoplasm associated with, 234
myeloid neoplasms associated with, 224–225
transient abnormal myelopoiesis in, 227
- early T-cell precursor lymphoblastic leukemia (ETP-ALL), flow cytometry plots, 137
- ehrlichiosis, 26
- eosinophilia, hypereosinophilia, 253
- Epstein-Barr virus (EBV), 55
hemophagocytic lymphohistiocytosis (HLH), EBV-induced, 269
infectious mononucleosis, 55, 58
monomorphic posttransplant lymphoproliferative disorder, DLBCL, EBV positive, 102
polymorphic posttransplant lymphoproliferative disorder, EBV positive, 101
systemic EBV-positive T-cell lymphoma of childhood, 86, 88
X-linked lymphoproliferative syndrome and, 112, 238
see also posttransplant lymphoproliferative disorders (PTLDs)
- Erdheim-Chester disease (ECD), 258, 262
- essential thrombocythemia (ET), 176–7, 181–2
- Ewing sarcoma (ES), 277
- FAB L1 lymphoblasts, 127
- FAB L2 lymphoblasts, 128
- Fanconi anemia (FA), 218
- folate/vitamin B12/copper deficiency, 28
- follicular hyperplasia (FH), 31
- follicular lysis, 31, 32
- Gaucher disease, 286
- gelatinous transformation/serous fat atrophy, 274
- germline predisposition
lymphoid neoplasm with, 230–45
myeloid neoplasms with, 207–225
- Glanzmann's thrombasthenia, 19, 20
- glucose 6-phosphate isomerase (GPI) deficiency, 10
- glucose-6-phosphate dehydrogenase (G6PD) deficiency, 9
- glycoprotein deficiency, 19–20
- Gorham disease, 278
- gray platelet syndrome, 21
- Heinz bodies, 2, 9
- hemoglobinopathies
hemoglobin C, 13
sickle cell disease, 12
thalassemia syndromes, 12
- hemophagocytic lymphohistiocytosis (HLH), 112, 120
risk of for Chediak-Higashi syndrome patients, 17
- hereditary elliptocytosis (HE), 11
- hereditary pyropoikilocytosis (HPP), 11
- hereditary spherocytosis (HS), 10–11
- Hermansky-Pudlak syndrome (HPS), 21
- hexokinase (HK) deficiency, 10
- high-grade B cell lymphoma with myc and BCL-2 and/or BCL-6 rearrangement, 69
- histiocytic disorders, 257, 269
Erdheim-Chester disease, 258, 262
hemophagocytic lymphohistiocytosis (HLH), 264
diagnostic criteria, 258
EBV-induced, 269
histiocytic sarcoma, 261, 267
indeterminate cell histiocytosis, 258
juvenile xanthogranuloma, 258–60
liver and bone marrow, 264
- Langerhans cell histiocytosis, 257–8
bone, 260
cutaneous, 259
gastrointestinal tract, 261
lymph node, 259
- Langerhans cell sarcoma, 261, 268
reticulohistiocytoma, 260, 265
Rosai-Dorfman disease, 260–1, 266
skin lesions, 262
- histoplasmosis infection, 53, 56
- HIV infection
lymphadenopathy and, 31, 57–8, 122, 123
lymphoproliferations associated with, 118, 124
- Hodgkin lymphomas (HLs), 90–4
classic HL, 90
CH PTLD, 99
lymphocyte-depleted subtype, 90–2
lymphocyte-rich subtype, 90
mixed cellularity subtype, 90
nodular sclerosis subtype, 90, 91
nodular lymphocyte predominant HL, 92–4
- human toxoplasmosis, 53, 57
- hyper IgM syndrome, 107, 114
- hyperplasia
mantle zone, 31, 32
marginal zone (monocytoid B-cell), 31, 32
paracortical/interfollicular, 31, 32
plasmacytoid dendritic cell, 31, 32
see also follicular hyperplasia (FH)
- idiopathic/immune thrombocytopenia purpura (ITP), 22–3
- immunodeficiency-associated lymphoproliferative disorders (IA-LPDs), 106–23
ataxia-telangiectasia, 106, 111
autoimmune lymphoproliferative syndrome (ALPS), 114, 122
chronic granulomatous disease, 110, 118
combined immunodeficiencies, 107, 115
common variable immunodeficiency, 110–16
defects of phagocytes, 110, 119
DiGeorge syndrome, 22q11.2 deletion syndrome, 107
hemophagocytic lymphohistiocytosis, 112, 120
HIV infection-associated, 118, 124
hyper IgM syndrome, 107, 114
Nijmegen breakage syndrome, 106, 113
severe combined immunodeficiency, 109, 115
severe congenital neutropenia, 111, 119
syndromes of immune deficiency, 106–7
X-linked lymphoproliferative syndrome, 112, 120, 238–44
- indeterminate cell histiocytosis (ICH), 258
- infectious diseases, 26–9, 52–9
aspergillosis, 58, 62
babesiosis, 27
cat scratch disease, 52
coccidioidomycosis, 59
cytomegalovirus, 55
ehrlichiosis, 26
histoplasmosis infection, 53, 56
HIV infection, 57–8
infectious mononucleosis, 55, 58
leishmaniasis, 59
malaria, 26
mycobacterial lymphadenitis, 52–3
parvovirus B19, 59, 63
pertussis, 26
syphilis, 52
toxoplasmosis, 27
viral infections, 26
yeast infections, 26
- infectious mononucleosis, 55, 58, 100
- iron deficiency, 27
diagnosing in young children, 44
iron excess, therapy-related, 273

- juvenile myelomonocytic leukemia (JMML), 186
 CBL mutation, **189**
 extramedullary involvement, **192**
 genetic subtypes, 187
 juvenile xanthogranuloma (JXG), 258–60
- Kikuchi-Fujimoto disease (KFD), 32, 33, 37
- Kimura disease, 33, 37
- Langerhans cell histiocytosis (LCH), 257, **261**
 bone, **260**
 cutaneous, **259**
 gastrointestinal tract, **261**
 lymph node, **259**
- Langerhans cell sarcoma (LCS), 261, **268**
- lead poisoning, 28
- leishmaniasis, 59
- leukemoid reaction, in newborn smear, 4
- Li-Fraumeni syndrome (LFS), 214, 233, lymphadenitis
- mycobacterial, 52–3
 necrotizing granulomatous, 35
 non-caseating granulomatous, 35
- lymphadenopathy, 31, 52
 branchial cleft cyst of lymph node and, 33, 41
- Castleman disease, 31, 32, 33,
 hyaline vascular variant, 35
 plasma cell variant, 36
 caused by infectious diseases, 52–9
see also infectious diseases.
- dermatopathic LAD, 33, 34
 extramedullary hematopoiesis and, 33, 40
- follicular hyperplasia, 33
 follicular lysis, 31, 32
 granulomatous LAD, 33
 HIV-associated
 type I pattern, **122**
 type III pattern, **123**
- inflammatory myofibroblastic tumor of lymph node, 39
- Kikuchi-Fujimoto disease, 32, 33, 37
- Kimura disease, 33, 37
- mantle zone hyperplasia, 31, 32
- marginal zone (monocytoid B-cell) hyperplasia, 31, 32
- necrotizing granulomatous lymphadenitis, 35
- non-caseating granulomatous lymphadenitis, 35
- paracortical/interfollicular hyperplasia, 31, 32
- plasmacytoid dendritic cell hyperplasia, 31, 32
- progressive transformation of germinal centers, 31, 33
- Rosai-Dorfman disease, 33, **38**
- sinus histiocytosis, 31, 32
- systemic lupus erythematosus and, 33, 40
- vascular transformation of lymph node sinuses and, 33, 41
- lymphocytes and neutrophils, in newborn smear, 3
- lymphoid neoplasm with germline predisposition, 230–45
- activated PI3K δ syndrome, 235
- ALL with *ETV6* mutation, 230
- ALL with *IKZF1* mutation, 230
- ALL with *PAX5* mutation, 230
- ataxia telangiectasia, 106, **111**, 241
- autoimmune lymphoproliferative syndrome (ALPS), 234, **237**
- characteristics, **232**
- CTLA4* haploinsufficiency, 236, **239**
- Down syndrome, 234
- Li-Fraumeni syndrome, 233
- severe combined immunodeficiency, 109, **115**, 236–42
- Wiskott-Aldrich syndrome, 23, 242
- X-linked lymphoproliferative (XLP)-1 syndrome, 238, **244**
- malaria, 26
- marginal zone lymphoma, 71–4
- mastocytosis, 247–8
 indolent systemic mastocytosis, **251**
 mast cell sarcoma, **249**
 mastocytoma of skin, **248**
 systemic mastocytosis with associated hematologic neoplasms, **252**
- systemic mastocytosis with extensive gastrointestinal involvement, **250**
- urticaria pigmentosa, **249**
- mature plasmacytoid dendritic cell proliferation (MPDCP), 140, **146**
- May-Hegglin disease, 17
- membranopathies
 acanthocytosis, 11–12
 hereditary elliptocytosis, 11
 hereditary pyropoikilocytosis, 11
 hereditary spherocytosis, 10–11
 Southeast Asian ovalocytosis, 11
 stomatocytosis, 11
- methylen blue stain, 2
- mononucleosis, infectious, 55, **58**, **100**
- mycobacterial lymphadenitis, 52–3
- myelodysplastic syndrome (MDS), *see also* childhood myelodysplastic syndrome (MDS), 198
- myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), 186, **197**
- chronic myelomonocytic leukemia, 187, **196**
- juvenile myelomonocytic leukemia, 186
 CBL mutation, **189**
 extramedullary involvement, **192**
 genetic subtypes, 187
 patient with NF1, **188**
- MDS/MPN-U, 187, **197**
- Noonan syndrome, 186, **190**
- RAS-associated autoimmune leukoproliferative disorder, 187, **194**
- myeloid neoplasms with germline predisposition, 207–225
- AML with germline *CEBPA* mutation, 210
- ANKRD26* mutation, 210, **213**
- characteristics, **208–9**
- DDX41* mutation, 210
- Diamond-Blackfan anemia, 220
- Down syndrome-associated, 224–225
- ETV6* mutation, 211, **214**
- Fanconi anemia, 218
- GATA2* mutation, 213–14
- inherited bone marrow failure syndromes, 209
- Li-Fraumeni syndrome, 214
- MECOM*-associated syndrome, 221
- RUNX1* mutation, 210, **212**
- SAMD9/SAMD9L* mutations, 220–221
- severe congenital neutropenia, 220, **224**
- Shwachman-Diamond syndrome, 218–219
- telomeropathies, 217
- myeloid sarcoma (MS), 150
- myeloproliferative neoplasms (MPNs), 176, **184**
- chronic eosinophilic leukemia not otherwise specified (CEL, NOS), 249
- chronic neutrophilic leukemia, 178
- essential thrombocythemia, 176–7, **181–2**
- polycythemia vera, 177, **182**
- primary myelofibrosis, 177–8, **183**
- unclassifiable (MPN-U), 178, **184**
- natural killer (NK) cell neoplasms, 78
- necrotizing granulomatous lymphadenitis, 35
- neuroblastoma (NBL), 275, **279**
- neutrophil function disorders, 17–18
- Barth syndrome, 18
- Chediak-Higashi syndrome, 17
- May-Hegglin disease, 17
- WHIM syndrome, 17

Index

- Niemann-Pick disease, 287
- Nijmegen breakage syndrome (NBS), 106, 113
- nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 90–4
- non-caseating granulomatous lymphadenitis, 35
- non-Hodgkin lymphomas (NHLs), 65
- children vs. adults, 65
- mature B-cell, 65–74
- Burkitt lymphoma, 65
- Burkitt-like lymphoma with 11q aberration, 65–7
- diffuse large B-cell lymphoma, 67, 72
- high-grade B-cell lymphoma with myc and BCL-2 and/or BCL-6 rearrangement, 69
- marginal zone lymphoma, 71–4
- pediatric type follicular lymphoma, 69–71
- primary mediastinal large B-cell lymphoma (PMLBCL), 69
- mature T-cell, 78–88
- anaplastic large cell lymphoma
- ALK negative, 78–86
- ALK positive, 78
- extranodal NK-/T-cell lymphoma, nasal type, 83, 86–7
- peripheral T-cell lymphoma NOS, 84, 88
- primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, 85, 88
- systemic EBV-positive T-cell lymphoma of childhood, 86, 88
- Noonan syndrome, 186, 190
- nucleated RBC, in newborn smear, 2
- nutritional disturbances, 27–9
- folate/vitamin B12/copper deficiency, 28
- iron deficiency, 27
- lead poisoning, 28
- osteopetrosis, 278
- overhydrated stomatocytosis, 11
- oxalosis, 278
- paracortical/interfollicular hyperplasia (PIH), 31, 32
- paroxysmal cold hemoglobinuria (PCH), 13
- parvovirus B19, 59, 63
- Pearson syndrome, 272
- pediatric-type follicular lymphoma (PTFL), 69–71
- peripheral blood smear evaluation, 1–6
- erythrocytes, 3
- leukemoid reaction, 4
- lymphocytes and neutrophils, 3
- nucleated RBC, 3
- platelets, 3–4
- red blood cell and reticulocyte indices, 3
- reticulocyte index, 2
- SARS-CoV-2, 6
- sepsis, 4
- slide preparation, 1
- stress responses, 5
- supravital stain, 50x, 2
- toxic granulations, 5
- viral infections, 4
- peripheral T-cell lymphoma, 33, 82, 84–7, 88
- pertussis, 26
- plasmacytoid dendritic cell (PDC) hyperplasia, 31, 32
- platelet disorders, 19–24
- Bernard-Soulier syndrome, 20
- Glanzmann's thrombasthenia, 19
- glycoprotein deficiency, 19–20
- gray platelet syndrome, 21
- Hermansky-Pudlak syndrome, 21
- idiopathic/immune thrombocytopenia purpura (ITP), 22–3
- storage pool deficiency, 20
- thrombotic thrombocytopenic purpura (TTP), 23–4
- Wiskott-Aldrich Syndrome, 23
- polyclonal plasmacytic hyperplasia, 33
- polycythemia vera (PV), 177, 182
- posttransplant lymphoproliferative disorders (PTLDs), 98–9
- classic HL, 99
- monomorphic, 99
- non-destructive, 98, 100
- polymorphic, 98
- precursor lymphoblastic leukemia/lymphoma, *see also*
- Bymphoblastic leukemia/lymphoma (B-LL/B-BL)
- Tymphoblastic leukemia/lymphoma (T-LL/LBL), 127, 137
- primary myelofibrosis (PMF), 177–8, 183
- progressive transformation of germinal centers (PTGC), 31, 33
- pure erythroid leukemia, 166
- pyruvate kinase (PK) deficiency, 9
- radiation effect, 273
- RAS-associated autoimmune leukoproliferative disorder (RALD), 187, 194
- reactive follicular hyperplasia, 31
- red blood cell disorders, 9–13
- autoimmune hemolytic anemia, 13
- associated conditions, 15
- cold agglutinin syndrome, 13
- mixed AIHA, 13
- paroxysmal cold hemoglobinuria, 13
- secondary AIHA, 13
- warm AIHA, 13
- enzyme deficiencies, 9–10
- G6PD deficiency, 9
- GPI deficiency, 10
- HK deficiency, 10
- PK deficiency, 9
- TPI deficiency, 10
- hemoglobinopathies
- hemoglobin C, 13
- sickle cell disease, 12
- thalassemia, 12
- membranopathies
- acanthocytosis, 11–12
- hereditary elliptocytosis, 11
- hereditary pyropoikilocytosis, 11
- hereditary spherocytosis, 10–11
- Southeast Asian ovalocytosis, 11
- stomatocytosis, 11
- refractory cytopenia of childhood (RCC), 199–200, 202, 203
- reticulohistiocytoma (RH), 260, 265
- retinoblastoma, 282
- rhabdomyosarcoma (RMS), 277, 281
- Rosai-Dorfman disease (RDD), 33, 38, 260–1, 266,
- sarcoma
- histiocytic sarcoma (HS), 261, 267
- Langerhans cell sarcoma, 261, 268
- SARS-CoV-2, in newborn smear, 6
- Schwachman-Diamond syndrome (SDS), 218–219
- sepsis, in newborn smear, 4
- severe combined immunodeficiency (SCID), 109, 115, 236–42
- severe congenital neutropenia (SCN), 111, 119, 220–4
- sickle cell disease (SCD), 12
- sideroblastic anemia, 270, 272
- sinus histiocytosis, 31, 32
- Southeast Asian ovalocytosis (SAO), 11
- stomatocytosis, 11
- storage-related disorders
- Gaucher disease, 286
- Niemann-Pick disease, 287
- storage pool deficiency, 20
- Wolman disease/lysosomal acid lipase deficiency, 288
- supravital stain, 2
- syphilis, 52
- systemic lupus erythematosus (SLE), 33, 40
- telomeropathies, 217, 221
- Tetralogy of Fallot, 17

- thalassemia, 12, 15
 therapy-related effects
 bone marrow thrombosis, 274
 childhood myelodysplastic syndrome (MDS), 201
 colony-stimulating factor therapy effect, 273
 gelatinous transformation/serous fat atrophy, 274
 iron excess, 273
 lymphoblastic leukemia, 272
 radiation effect, 273
 therapy-related myeloid neoplasms, AML, 148–50
- thrombotic thrombocytopenic purpura (TTP), 23–4
 T-lymphoblastic leukemia/lymphoma (T-ALL/LBL), 135, 137
 EPT-ALL, 137, 138
 toxic granulations, in newborn smear, 5
 toxoplasmosis, 27
 triosephosphate isomerase (TPI) deficiency, 10
 viral infections, 26
 in newborn smear, 4
- WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), 17
 Wiskott-Aldrich syndrome (WAS), 23, 242
 Wolman disease/lysosomal acid lipase deficiency, 288
 Wright stain, 2
 Wright-Giemsa stain, 2
- xerocytosis, 11
 X-linked lymphoproliferative syndrome (XLP), 112, 120, 238–44
 yeast infections, 26